Study of Renin Levels and Response to Synthetic Angiotensin II in Adults with Vasoplegic Shock

What this Trial Is About

Shock is a serious condition that can cause multiple organs to fail and can be life-threatening. This research focuses on patients with distributive shock who have low blood pressure despite receiving common vasopressor drugs like noradrenaline and vasopressin. The study evaluates the relationship between renin levels, an enzyme involved in blood pressure regulation, and the use of synthetic angiotensin II, a drug given when standard vasopressors are not enough. Researchers aim to understand which patients might benefit most from angiotensin II treatment based on renin concentration changes. Participants who are adults with distributive shock not responding adequately to noradrenaline and vasopressin will receive an infusion of angiotensin II starting at 20 ngkgmin, adjustable up to 40 ngkgmin as needed. Blood samples will be taken before the infusion and six hours afterwards to measure renin levels. This observational study will track how renin changes during treatment and how it relates to clinical outcomes. During the study, researchers will monitor the number of days patients remain free from organ failure and days spent outside the intensive care unit over 30 days. They will also assess the duration of vasopressor need, the requirement for mechanical ventilation or dialysis, and trends in renin levels within the first six hours. The study participation will last up to 30 days, with close observation of patient responses to angiotensin II and their overall clinical progress.

Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II.